Inhibitory peptides against coronaviruses
AssigneeThe Trustees of Columbia University in the City of New York
InventorsMasayuki YAZAWA, Ramsey BEKDASH, Kazushige YOSHIDA, David D. HO, Yaoxing HUANG, Manoj NAIR
Life of this patent
Estimating the term…
Abstract
The present inhibitory polypeptides/peptides are derived from an envelope (E) protein of a coronavirus (e.g., human coronaviruses such as SARS-CoV-2). The polypeptides/peptides against coronaviruses can be used to treat or prevent infection by a coronavirus in a subject.
Claims32
A fusion polypeptide, comprising:
- (i) a cell-penetrating peptide;
- and
- (ii) a coronavirus peptide comprising a fragment of an envelope (E) protein of a coronavirus.
The fusion polypeptide of any preceding claim, wherein the coronavirus peptide comprises at least one glutamic acid to aspartic acid mutation, and/or at least one aspartic acid to glutamic acid mutation.
The fusion polypeptide of any preceding claim, wherein the coronavirus peptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO:
- 1, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 22, or SEQ ID NO:
- 24.
The fusion polypeptide of any preceding claim, wherein the coronavirus peptide comprises an amino acid sequence set forth in SEQ ID NO:
- 2, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 18, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 23 or SEQ ID NO:
- 25.
The fusion polypeptide of any preceding claim, wherein the cell-penetrating peptide is TAT, 6-Arg or Penetratin.
The fusion polypeptide of any preceding claim, wherein the cell-penetrating peptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO:
- 4, SEQ ID NO:
- 5 or SEQ ID NO:
- 6.
The fusion polypeptide of any preceding claim, wherein the cell-penetrating peptide is directly linked to the coronavirus peptide.
The fusion polypeptide of any preceding claim, further comprising a linker connecting the cell-penetrating peptide and the coronavirus peptide.
The fusion polypeptide of any preceding claim, wherein the fusion polypeptide is PEGylated.
The fusion polypeptide of any preceding claim, wherein the cell-penetrating peptide is located at the N-terminus of the fusion polypeptide.
The fusion polypeptide of any preceding claim, comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO:
- 7, SEQ ID NO:
- 9 or SEQ ID NO:
- 10.
The fusion polypeptide of any preceding claim, comprising an amino acid sequence set forth in SEQ ID NO:
- 3 or SEQ ID NO:
- 8.
A coronavirus peptide, having about 10 to about 30 amino acid residues in length, wherein the coronavirus peptide has an amino acid sequence at least 70% identical to a consecutive amino acid sequence within position 1 to position 40 of an envelope (E) protein of a coronavirus.
The fusion polypeptide or the coronavirus peptide of any preceding claim, wherein the coronavirus is a human coronavirus.
The fusion polypeptide or the coronavirus peptide of any preceding claim, wherein the coronavirus is SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 or HCoV-HKU1.
A kit comprising the fusion polypeptide, the coronavirus peptide, or the pharmaceutical composition of any preceding claim.
Dependencies are inferred from the claim text.